Business Segment Information - Summary of EBIDTA by Reporting Segment (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Consolidated adjusted EBITDA		$ 46,285	$ 48,553	$ 61,262
Interest expense, net		8,631	1,288	1,837
Depreciation and amortization		53,063	29,019	41,355
Share-based compensation expense		35,707	18,443	15,432
Foreign exchange impact		(1,581)	3,291	3,981
SeaSpine merger-related costs		36,623	12,010
Strategic investments		2,272	4,018	5,700
Acquisition-related fair value adjustments		33,393	(15,595)	(2,014)
(Gain) loss on investments		1,781	187	(644)
Litigation and investigation costs		14,453	803	33
Medical device regulation		9,446	10,261	8,018
Business interruption - COVID-19			2,387	320
Succession charges	$ 18,200	1,176	147	739
Income (loss) before income taxes		(148,679)	(17,706)	(13,495)
Operating Segments [Member] | Global Spine [Member]
Segment Reporting Information [Line Items]
Consolidated adjusted EBITDA		91,115	62,692	71,086
Operating Segments [Member] | Global Orthopedics [Member]
Segment Reporting Information [Line Items]
Consolidated adjusted EBITDA		442	5,267	9,260
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Consolidated adjusted EBITDA		$ (45,272)	$ (19,406)	$ (19,084)